Bulletin
Investor Alert

Topics

Insulin

1:47 a.m. Dec. 7, 2021 - Barrons.com
Omicron Fears Are Easing. The Santa Rally Could Be Back On. New York City workers under new Covid-19 vaccine mandate, Intel plans IPO of Mobileye self-driving-car unit, Biden touts prescription drug savings in spending plan, and other news to start your day.
10:14 a.m. Dec. 6, 2021 - By Robert Schroeder
Biden promises Build Back Better plan will slash 'outrageously expensive' drug prices as Democrats push to pass bill before ChristmasPresident Joe Biden promoted the parts of his massive social-spending bill that are designed to curb drug prices in a White House speech on Monday, as top Democrats are pushing to pass the legislation by Christmas.
5:21 a.m. Nov. 27, 2021 - By Alessandra Malito
Build Back Better — what’s in it for seniors?These provisions would help current and future retirees — if they pass the Senate
6:32 a.m. Nov. 23, 2021 - By Paul Brandus
This Thanksgiving, seniors have much to be thankful forThe simple act of getting together will be something to celebrate
5:32 a.m. Nov. 20, 2021 - By Karen Van Nuys
Middlemen, not drug companies, are pushing up insulin prices, and Congress doesn't have the right plan to fight backWhy should those who distribute insulin, such as pharmacy-benefit managers, get more than half of the money spent by consumers?
3:46 a.m. Nov. 9, 2021 - By Victor Reklaitis
Here's what’s in and out of Democrats’ big social-spending plan — for nowAs the Democratic party tries to reach agreement, here are key proposed categories for the spending, along with the types of tax hikes planned.
3:36 p.m. Nov. 5, 2021 - Barrons.com
Gene Therapy Is a Huge Opportunity. It Pays to be Patient. Biotechs and big pharma companies are targeting diabetes, cardiovascular problems, and even wrinkles. This is one opportunity where it pays to be patient.
9:00 a.m. Nov. 5, 2021 - By Alessandra Malito
News and analysis for those planning for or living in retirementRetirement news and analysis
6:00 p.m. Nov. 4, 2021 - MarketWatch.com
House Democrats aim to vote on infrastructure, social-spending bills Friday Democrats in the House appear on the verge of advancing President Joe Biden’s $1.85 trillion-and-growing domestic policy package alongside a companion $1 trillion infrastructure bill in what would be a dramatic political accomplishment — if they can push it to passage.
12:30 p.m. Nov. 3, 2021 - MarketWatch.com
House Democrats add SALT relief, paid leave, immigration changes to social-spending billHouse Democrats added paid family and medical leave, immigration law changes and a state-and-local tax break to their $1.75 trillion social services and environmental bill Wednesday, reviving some key elements of President Joe Biden’s agenda as they rush to finish the package after dismal overnight election results.
6:07 a.m. Nov. 3, 2021 - By Paul Brandus
Biden intends to rein in soaring drug prices — including insulin. Here’s howPoliticians on both sides of the aisle have expressed alarm about the cost of prescriptions
11:21 a.m. Oct. 19, 2021 - By Alessandra Malito
80% of Medicare beneficiaries don’t know this rule — or its penaltyThese common misunderstandings could cost you
5:54 a.m. Oct. 16, 2021 - Barrons.com
This Small Biotech Is Partnering With Johnson & Johnson. The Stock Could More Than Double. MeiraGtx is quietly working on a promising new approach to gene therapy. Sizing up the opportunity, pondering the unknowns.
11:00 p.m. Oct. 6, 2021 - Barrons.com
Opinion: Congress' Plan to Cut Drug Costs Will Kill Life-Saving Innovation If the House Democrats plan passes, Eli Lilly will be forced to reduce R&D spending by more than 40%, writes CEO David A. Ricks.
8:28 a.m. Sept. 28, 2021 - Barrons.com
With Insulin Sales Shrinking in Importance, Lilly Cuts Price Lilly's move could help shift investors' attention from insulin to the company's growth markets in obesity and Alzheimer's disease.
1:41 a.m. Sept. 28, 2021 - By Ciara Linnane
Eli Lilly to reduce list price of Insulin Lispro injection by an additional 40% from Jan. 1, restoring it to 2008 levelsEli Lilly & Co. said Tuesday it is reducing the list price of Insulin Lispro Injection in the U.S. by another 40% effective Jan. 1, 2022, bringing the price down to 2008 levels. "Lilly's Insulin Lispro Injection, 100 units/mL -- first introduced at half the list price of branded Humalog(R) (insulin lispro injection, 100 units/mL) in 2019 -- will now have a 70% lower list price than Humalog U-100," the company said in a statement. People using any of Lilly's insulin products can fill their monthly prescription for $35 through the Lilly Insulin Value Program, for those with commercial insurance or who are uninsured, while seniors can use a program that is part of Medicare Part D plans. "We hope this additional 40 percent cut can expand affordable insulin to more people with diabetes," Lilly Chief Executive David Ricks said in a statement. Lilly shares were down 0.4% premarket.
Eli Lilly to reduce list price of Insulin Lispro injection by an additional 40% from Jan. 1
1:32 a.m. Sept. 28, 2021
8:06 a.m. Sept. 8, 2021 - By Home Media
Is the Medicare donut hole closed?The Medicare donut hole is closed in 2020. Find out more what this means for your prescription drug costs this year.
11:59 p.m. Sept. 6, 2021 - MarketWatch.com
10 ways to improve your health and live longerThere are some astonishing new technologies on the horizon that will help you to 'grow young.' Why not be around to experience some of them?
7:20 a.m. Sept. 4, 2021 - MarketWatch.com
Power to be restored to New Orleans by middle of next weekPower should be restored to New Orleans by the middle of next week, utility officials said Friday, and sheriff's deputies warned people returning to communities outside the city to come equipped like survivalists because of the lack of basic services in the aftermath of Hurricane Ida.
5:45 a.m. Aug. 30, 2021 - By Eleanor Laise
'I’ll be robbed twice in one lifetime': Retirees fearing financial disaster wait for pension rescueRetirees struggle to stay afloat while waiting for restoration of pension benefits. Here are some of their stories.
5:26 a.m. Aug. 25, 2021 - MarketWatch.com
Experts say Americans should start getting screened for diabetes earlier, now at age 35Overweight and obese Americans should start getting screened for diabetes earlier, at age 35 instead of 40, according to updated national guidelines published Tuesday.
11:30 p.m. Aug. 24, 2021 - Barrons.com
Don't Meddle with Medicare to Save a Budget Lawmakers want to allow Medicare to negotiate drug prices. That plan won’t fix the problems that are driving up the cost of medicines for patients, writes Stephen J. Ubl of PhRMA.
10:56 a.m. Aug. 16, 2021 - By Tonya Garcia
Walmart preview: U.S. sales growth at Walmart could outdo AmazonWalmart's grocery business is gaining strength as shoppers become more price sensitive, analysts say
7:08 a.m. Aug. 12, 2021 - Barrons.com
The Bull Case for Walmart’s Insulin Products Walmart's private-label insulin should further drive traffic and diversify revenue, and play a strong role in its healthcare efforts, Cowen says.
7:05 a.m. Aug. 10, 2021 - MarketWatch.com
U.S. groups make their own drugs to fight high drug prices and shortagesImpatient with years of inaction in Washington on prescription drug costs, U.S. hospital groups, startups and nonprofits have started making their own medicines in a bid to combat stubbornly high prices and persistent shortages of drugs with little competition.
3:12 a.m. July 29, 2021 - By Jaimy Lee
Viatris gets FDA approval of first biosimilar version of Sanofi's insulin LantusShares of Viatris Inc. gained 3.3% in premarket trading on Thursday, the day after the Food and Drug Administration approved the first biosimilar verson of insulin glargine from Viatris and Biocon Biologics Ltd. Biocon is a privately held biopharma company based in India. The newly approved treatment, Semglee, is a biosimilar and interchangeable version of Lantus, Sanofi's once-blockbuster long-actin insulin. Semglee will be sold exclusively by the companies for 12 months before the FDA can approve another biosimilar version of Lantus. Biosimilar drugs are copies of complex biologic drugs; this is somewhat similar to how generic drugs compare to brand-name prescription medications, in that that biosimilars and generic drugs are less expensive than the brand-name alternatives. Viatris shares are down 24.0% so far this year, while the broader S&P 500 is up 17.1%.
2:00 a.m. July 14, 2021 - By Ciara Linnane
Eli Lilly buys remaining shares of Protomer Technologies in glucose-responsive insulin playEli Lilly & Co. said Wednesday it is acquiring the shares of Protomer Technologies it does not already own, in a deal it says has a potential value of more than $1 billion based on future development and commercial milestones. Lilly had previously purchased a 14% stake in the company, which has a proprietary peptide- and protein-engineering platform that can be used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity. Protomer was founded in 2015 in Pasadena, California. "Protomer has used this approach toward advancing a portfolio of therapeutic candidates, including glucose-responsive insulins that can sense sugar levels in the blood and automatically activate as needed throughout the day," Lilly said in a statement. Lilly said the deal will not impact its 2021 non-GAAP EPS. Lilly shares were not yet active premarket, but have gained 39% in the year to date, while the S&P 500 has gained 16%.
8:06 a.m. June 29, 2021 - Barrons.com
Walmart Is Selling Its Own Insulin. What That Means for 3 Brand-Name Drug Makers. The discount chain's private label sells at prices more than 50% lower than brand names made by Lilly, Sanofi, and Novo Nordisk.
4:03 a.m. June 29, 2021 - By Wallace Witkowski
Walmart to launch lower-priced insulin offering savings of up to 75% Walmart Inc. said Tuesday it is launching a lower priced brand of insulin because it is working directly with the manufacturer, Novo Nordisk.
4:48 a.m. June 19, 2021 - By Thornton McEnery
Meme-stock traders start to converge on shares of insulin-monitor maker SenseonicsSenseonics is flying as high short interest and a huge surge in social media mentions fuels another “Memic Monday.”
11:40 a.m. June 14, 2021 - By Joy Wiltermuth
Nasdaq, S&P 500 end at records as stocks finish mostly higher ahead of Fed updateU.S. stock indexes finish mostly higher Monday, with tech shares lifting the Nasdaq Composite and S&P 500 to fresh record closes, as investors ready for an important meeting of the Federal Reserve this week.
7:00 a.m. June 14, 2021 - By MarketWatch
Meme-stock traders start to converge on shares of insulin-pump maker SenseonicsSenseonics is flying as high short interest and a huge surge in social media mentions fuels another “Memic Monday.”
9:06 a.m. June 5, 2021 - By Quentin Fottrell
One delicious way to cut your risk of Type 2 diabetes, according to a study of 7,000 people An estimated 374 million people are at increased risk of developing Type 2 diabetes, researchers sayAn estimated 374 million people are at increased risk of developing Type 2 diabetes, researchers say.
7:30 a.m. May 9, 2021 - MarketWatch.com
Biden administration set to ramp up vaccine diplomacy in drive to inoculate world against COVID-19Controversial move to waive patent protections for vaccines is a key element.
3:11 a.m. April 27, 2021 - Barrons.com
Eli Lilly Cuts Earnings Forecast as Profits Fall Short The drugmaker scaled back its earnings guidance for the full 2021 fiscal year, mainly due to weaker-than-expected sales of Covid-19 antibodies.
3:30 p.m. April 16, 2021 - Barrons.com
Bitcoin and Its Greatest Threat Letters on Bitcoin and other cryptocurrencies, liquid biopsies, and debt-fueled growth
2:14 p.m. March 22, 2021 - Barrons.com
Insulet Stock Rises as It Joins the Automated Insulin Device Competition The company's popular insulin pumps demonstrated the ability to automatically regulate glucose levels for their diabetic users.
3:05 a.m. March 12, 2021 - MarketWatch.com
The best reason to dump the whole 'fall back" and 'spring forward' routine: your sleep-deprived selfDrop daylight saving time and boost your health.
9:37 a.m. March 11, 2021 - By Home Media
Medicare changes 2021: What you need to knowHere’s what you need to know about the changes to Medicare coverage, costs, and benefits in 2021.
Browse topics:
Link to MarketWatch's Slice.